Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
VED
АТХ:A.10.B.B.01 Glibenclamide
Pharmacodynamics:The sulfonylurea compound II generation, by reducing the threshold of stimulation of pancreatic β-cells by glucose stimulates the secretion of insulin, increases its release and the degree of binding to target cells. The hypoglycemic effect depends on the number of functioning β-cells.
Suppresses platelet aggregation, has fibrinolytic, hypolipidemic and weak diuretic action.
Pharmacokinetics:After oral intake absorbed in the gastrointestinal tract by 90%. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 95%.
The maximum therapeutic effect develops 7-8 hours after admission. The duration of action is 12 hours. Metabolism in the liver.
The half-life is 2-10 hours. Elimination by the kidneys and with feces.
Indications:It is used for the treatment of non-insulin dependent diabetes mellitus.
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
Contraindications:Diabetes I type (insulin-dependent), coma, ketoacidosis, individual intolerance.
Carefully:Concomitant diseases of the endocrine system affecting carbohydrate metabolism: adenohypophysis and adrenocortical insufficiency, dysfunction of the thyroid gland.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, 30-60 minutes before meals before breakfast or 2 times a day. The initial dose is 1-1.5 mg per day, can be increased to 10-15 mg per day.
The highest daily dose: 20 mg.
The highest single dose: 20 mg.
Side effects:Hemopoietic system: rarely - thrombocytopenia, erythrocytopenia, granulocytopenia, hemolytic anemia.
Digestive system: dyspepsia, nausea, vomiting, diarrhea, hepatitis, cholestatic jaundice.
Musculoskeletal system: arthralgia.
Dermatological reactions: a rash.
Urinary system: proteinuria.
Allergic reactions.
Overdose:Development of hypoglycemia.
Treatment: sugar inside, with loss of consciousness - intravenous injection of 40% dextrose solution. Effective hemodialysis.
Interaction:Increase the concentration of the drug in the blood plasma inhibitors of the isoenzyme 3A4 cytochrome P450: ketoconazole, ciclosporin, erythromycin.
Reduced glycemic control while applying the drug to the thiazide diuretics, calcium channel blockers slow, lithium preparations, glucocorticoids, isoniazid, sympathomimetics, nicotinic acid, phenytoin, phenothiazines, thyroid hormones.
With simultaneous application with furosemide, a dose reduction is necessary.
The use of alcohol (especially on an empty stomach) during treatment promotes the development of disulfiram-like reactions and increases the risk of hypoglycemia.
Special instructions:During pregnancy and lactation, the drug is canceled, the treatment of diabetes continues with injections of insulin.